

PRODUCT MONOGRAPH

Pr AURO-CEPHALEXIN

Cefalexin Tablets, BP

250 mg and 500 mg

Antibiotic

Auro Pharma Inc.

3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada

Submission Control: 231234

Date of Revision:
September 11, 2019.

PRODUCT MONOGRAPH

Pr AURO-CEPHALEXIN

Cefalexin Tablets, BP

250 mg and 500 mg

THERAPEUTIC CLASSIFICATION

Antibiotic

ACTION

Cefalexin is bactericidal against many gram-positive and gram-negative organisms. *In vitro* tests demonstrate that the cephalosporins are bactericidal through their inhibition of cell-wall synthesis ⁽¹⁵⁾.

INDICATIONS

AURO-CEPHALEXIN may be indicated for the treatment of bacterial infections of the respiratory tract ^{(1,12)(13,14)}, including otitis media ^(1,2), genitourinary tract ⁽³⁾, bones and joints ^(4,5), skin and soft tissue ^(6,7) when the infection is caused by susceptible organisms. Culture and susceptibility studies should be performed.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefalexin and other antibacterial drugs, AURO-CEPHALEXIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

AURO-CEPHALEXIN is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

WARNINGS

Before therapy with AURO-CEPHALEXIN is instituted, careful inquiry should be made concerning previous hypersensitivity reactions to cephalosporins, penicillins or other drugs.

AURO-CEPHALEXIN should be given only with caution to penicillin-sensitive patients. There is some evidence of cross-allergenicity between the penicillins and the cephalosporins. Patients have been reported to have had severe reactions (including anaphylaxis) to both.

Antibiotics including AURO-CEPHALEXIN should be administered with caution, and then only when absolutely necessary, to any patient who has demonstrated some form of allergy, particularly to drugs. Of 12,917 clinical trial patients, 462 had histories of penicillin allergy⁽⁸⁾. Twenty-one of them (about 4.6 percent) were among those in whom possible allergic reactions to cefalexin were observed.

Gastrointestinal

Clostridium difficile-associated disease

Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including cefalexin. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of *Clostridium difficile*. *C. difficile* produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridium difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridium difficile*. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe case (see ADVERSE REACTIONS).

Susceptibility/Resistance

Development of Drug-Resistant Bacteria

Prescribing AURO-CEPHALEXIN in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.

PRECAUTIONS

As is the case with all drugs, patients should be followed carefully so that adverse reactions or unusual manifestations of drug idiosyncrasy may be detected. If an allergic reaction to AURO-CEPHALEXIN occurs, the drug should be discontinued and the patient treated with the usual agents (e.g., epinephrine or other pressor amines, antihistamines, or corticosteroids).

Prolonged use of AURO-CEPHALEXIN may result in overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If super infection occurs during therapy, appropriate measures should be taken.

AURO-CEPHALEXIN should be administered with caution in the presence of markedly impaired renal function. Under such conditions, careful clinical observation and laboratory studies should be made because safe dosage may be lower than that usually recommended.

If AURO-CEPHALEXIN is to be used for long-term therapy, periodic monitoring of hematology, renal and hepatic functions should be done.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy; e.g., the incision and drainage of abscesses.

Safety of this product for use during pregnancy has not been established.

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs' test may be due to the drug.

In patients being treated with AURO-CEPHALEXIN, a false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with Clinitest tablets, but not with Tes-Tape® (Glucose Enzymatic Test Strip, USP).

ADVERSE REACTIONS

Of 12,917 patients treated with cefalexin in formal clinical trials, 771(6%) reported adverse events, of which 385 (3%) were judged to be drug-related ⁽⁸⁾. Four hundred and sixty-two of these patients had known sensitivity to penicillin, 4.6% reacted. The incidence of reported side effects is shown in Table 1:

TABLE 1: Adverse Events Reported in 12,917 Patients Treated with cefalexin

	Relationship to Drug				
	Probable/definite	Uncertain	Discontinued Treatment	Total Reports	Percent
Gastrointestinal					
Diarrhea	87	77	31	164	1.3
Nausea	72	62	24	134	1.0
Vomiting	38	44	24	82	0.6
Dyspepsia/G.I. upset	24	7	5	31	0.2
Abdominal cramp/pain	9	8	5	17	0.1
Anorexia	11	6	2	17	0.1
Hypersensitivity					

Skin rash	52	42	42	94	0.7
Urticaria	22	12	19	34	0.3
Central Nervous System					
Headache	7	11	6	18	0.1
Genitourinary					
Genital Moniliasis	42	11	6	53	0.8
Vaginitis	15	11	4	26	0.4
Pruritus Vulvae	10	5	-	15	0.2

Other adverse reactions experienced less frequently include: glossitis/stomatitis, oral moniliasis, pruritus ani, gastroenteritis, fever, pruritus, a positive direct Coombs', allergy/anaphylaxis, intertrigo, angioedema, dizziness, paresthesia, somnolence, visual hallucination/diplopia, insomnia, tremor, leucorrhea, dysuria, malaise/fatigue, super infection, myalgia/back pain, nuchal swelling, dyspnea, cardiac arrhythmia and vasodilatation.

One hundred and seventy patients (1.3%) had abnormal laboratory values. There was no consistent pattern of abnormality and only 2 patients were withdrawn from studies as a result of these findings.

TABLE 2: Abnormal Laboratory Values

	Relationship to drug			
	Probable/Definite	Uncertain	Total Reports	Percent
Hematological				
Eosinophilia	27	18	45	0.4
Biochemical				
Elev. Alk Phosphatase.	9	15	24	0.2
Elev. SGOT	11	21	32	0.3
Elev. SGPT	6	16	22	0.2
Renal				
Elev. BUN	3	11	14	0.1

Other abnormal values reported less frequently included: elevated creatinine, bilirubin and cholesterol; decreased platelets, hemoglobin and/or hematocrit.

The following adverse reactions have been reported during postmarketing experience:

Gastrointestinal

Symptoms of pseudomembranous colitis may appear either during or after antibiotic treatment. Nausea and vomiting have been reported. The most frequent side effect has been diarrhea. It was very rarely severe enough to warrant cessation of therapy. Dyspepsia and abdominal pain have also occurred. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported.

Hypersensitivity

Allergic reactions in the form of rash, urticaria, angioedema, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been observed.

These reactions usually subsided upon discontinuation of the drug. In some of these reactions, supportive therapy may be necessary. Anaphylaxis has also been reported.

Other reactions have included genital and anal pruritus, genital moniliasis, vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations, arthralgia, arthritis, and joint disorder. Reversible interstitial nephritis, eosinophilia, neutropenia, leukopenia, thrombocytopenia, and slight elevations in SGOT and SGPT have been reported.

Vertigo, tinnitus, hearing loss and behavioural changes in young children have been reported with cefalexin use.

OVERDOSAGE

Activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended.

Signs and Symptoms

Symptoms of oral overdose may include nausea, vomiting, epigastric distress, diarrhea, and hematuria. If other symptoms are present, it is probably secondary to an underlying disease state, an allergic reaction, or toxicity due to ingestion of a second medication.

Treatment

Unless 5 to 10 times the normal dose of cefalexin has been ingested, gastrointestinal decontamination should not be necessary.

Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.

Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cefalexin; however, it would be extremely unlikely that one of these procedures would be indicated.

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

DOSAGE AND ADMINISTRATION

AURO-CEPHALEXIN is administered orally. The adult dosage ranges from 1 to 4 g daily in divided doses. The usual adult dose is 1 g/day in divided doses every 6 hours. For more severe infections or those caused by less susceptible organisms, larger doses may be needed. If daily doses of AURO-CEPHALEXIN greater than 4 g are required, parenteral cephalosporins, in appropriate doses should be considered.

For the treatment of bacterial pharyngitis caused by *Streptococcus pyogenes* group A, and, acute cystitis, the daily dosage may be divided into two and given every 12 hours.

In severe infections, the dosage may be doubled.

In the treatment of beta-hemolytic streptococcal infections, AURO-CEPHALEXIN therapy should be administered for at least ten days.

To obtain maximum peak levels, AURO-CEPHALEXIN should be administered on an empty stomach.

PHARMACEUTICAL INFORMATION


Drug Substance:

Trade Name: AURO-CEPHALEXIN

Proper Name: Cefalexin Monohydrate

Chemical Name: (6R, 7R)-7-[[[(2R)-2-Amino-2-phenylacetyl] amino]-3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid monohydrate

Structural Formula:



Molecular Formula: C₁₆H₁₇N₃O₄S. H₂O

Molecular Weight: 365.4 g/mol

Description: White or almost white, crystalline powder.
Springly soluble in water, practically insoluble in ethanol (96 percent).

STORAGE AND STABILITY:

Store at room temperature (15°C to 30°C).
Keep out of reach and sight of children.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage form	Tablets	
Strength	250 mg	500 mg
Description	Orange coloured capsule shaped biconvex film coated tablets debossed with "L" on one side and "59" on the other side	Orange colored capsule shaped biconvex film coated tablets debossed with "L" on one side and with a score line in between "6" and "0" on the other side.
Composition	Medicinal ingredient: Cefalexin (as Cefalexin monohydrate). Non-medicinal ingredients: Sodium Starch Glycolate, Microcrystalline Cellulose, Magnesium Stearate, hypromellose, titanium dioxide, macrogol and FD&C Yellow #6 Sunset yellow FCF Aluminium Lake.	
Packaging	HDPE bottles of 100, 500 and 1000 tablets	

Comparative Bioavailability Studies

A double blind, randomized, two-treatment, two-sequence, two-period, cross-over, single-dose oral bioequivalence study of 1 x 500 mg AURO-CEPHALEXIN Tablets [Aurobindo Pharma Limited, India manufactured for Auro Pharma Inc. (Canada)] versus 1 x 500 mg APO-CEPHALEX® (Cephalexin Tablets USP) 500 mg [Apotex Inc., Canada] was completed in 26 healthy, adult, male, human subjects under fasting conditions. A summary of the bioavailability data is presented in the following table.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Cefalexin (1 X 500 mg) From measured data				
Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test*	Reference†	% Ratio of Geometric Means	90% Confidence Interval
AUC_{0→t} (hr. ng/mL)	44.9 46.5 (25.2)	44.2 45.7 (25.3)	101.7	99.1-104.4
AUC_{0→∞} (hr. ng/mL)	46.2 47.8 (25.6)	45.4 47.0 (25.5)	101.7	99.1-104.3
C_{max} (ng/mL)	19.8 20.6 (27.6)	20.6 21.6 (28.8)	95.7	85.9-106.7
T_{max}§ (h)	1.2 (0.7-3.0)	1.0 (0.33-2.50)		
T_{1/2}§ (h)	1.2 (13.3)	1.3 (17.0)		

*AURO-CEPHALEXIN (Cefalexin Tablets BP) 500 mg, by Auro Pharma Inc.

† APO-CEPHALEX® (Cephalexin Tablets USP) 500 mg, of APOTEX, INC., Canada were purchased from Canada.

§ Expressed as the median (range) only.

§ Expressed as arithmetic mean (% CV) only.

Cefalexin Tablets BP are “also known as Cephalexin”.

MICROBIOLOGY

Cefalexin is active against the following organisms *in vitro*:

Beta-hemolytic and other streptococci (many strains of enterococci; e.g., *Streptococcus faecalis*, are resistant).

Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains (a few strains of staphylococci are resistant to cefalexin).

<i>Streptococcus pneumoniae</i>	<i>Proteus mirabilis</i>
<i>Escherichia coli</i>	<i>Klebsiella pneumoniae</i>
<i>Hemophilus influenzae</i>	<i>Branhamella catarrhalis</i>

Cefalexin is not active against most strains of *Enterobacter sp.*, *Pr. Morganii*, and *Pr. vulgaris*. It has no activity against *Pseudomonas* or *Herellea* species. When tested by *in vitro* methods, staphylococci exhibit cross-resistance between Cefalexin and methicillin-type antibiotics.

Table 3 shows the tube dilution sensitivity data as supplied by several investigators.

TABLE 3⁽¹¹⁾. Susceptibility of Clinically Isolated Bacteria to Cefalexin Expressed as Cumulative Percent

ORGANISM	<u>MINIMUM INHIBITORY CONCENTRATION</u>						
	(mcg/mL)						
	NO. OF ISOLATES	#2	2.5 - 4	5-8	10-16	20-32	40-64
<i>Staph. aureus</i> (unspecified)	458	31	58	81	92	97	99
<i>Staph. aureus</i> (penicillin-resistant)	158	41	82	88	98	99	100
<i>Staph. aureus</i> (penicillin-sensitive)	171	68	84	98	100	100	100
<i>Staph. epidermidis</i>	42	29	62	83	91	95	95
<i>Str. pneumoniae</i>	259	57	94	100	100	100	100
<i>Str. pyogenes</i> (group A)	262	84	91	96	99	100	100
<i>E. coli</i>	1165	1	9	40	76	88	92
<i>Klebsiella sp.</i>	533	1	9	55	78	86	88
<i>Pr. mirabilis</i>	535	-	3	14	56	77	84
<i>H. influenzae</i>	258	18	33	62	88	99	100
<i>B. catarrhalis</i>	14	64	100	100	100	100	100

PHARMACOLOGY

Animal

In the dog, there is evidence to show that cefalexin is absorbed primarily at the site of the duodenum. In dogs given 10 mg/kg of cefalexin intravenously, intramuscularly and orally, the blood serum level was approximately the same after 1 hour and 45 minutes⁽⁹⁾. Most of the drug is excreted in the urine. In rats, 5% of the administered dose was recovered in the bile. The serum half-life in rats and mice is 1.5 hours and 45 minutes respectively. Insignificant amounts enter the cerebrospinal fluid of dogs and monkeys. Variable amounts can be recovered from the breast milk of rats. Cefalexin distributes well to various tissues of rats, particularly the liver and kidney (see Table 4).

TABLE 4: Cefalexin-¹⁴C tissue levels in rats and in mice after a single oral dose of cefalexin-¹⁴C (46 mcmoles/kg)

TISSUE	mcg Cefalexin/g Tissue			
	RAT	RAT	MOUSE	MOUSE
	1 Hour	4 Hours	1 Hour	4 Hours
Blood	3.71	2.09	3.59	0.53
Liver	17.11	7.25	12.96	1.93
Spleen	2.21	1.45	1.45	0.4
Kidney	39.93	23.69	27.23	3.53
Lung	3.38	2.58	1.63	0.30
Heart	1.52	1.09	3.31	1.07
Fat	1.54	0.80	1.41	0.34
Muscle	1.16	0.76	1.11	0.32
Brain	0.53	0.24	0.30	0.11

Human

Cefalexin is well absorbed orally to produce effective peak blood levels within 1 hour. (Figure 1)




Figure 1: Cefalexin Blood Levels with Various Doses (Fasting Subjects)

Less than 10% of absorbed cefalexin is bound to serum protein in concentrations above 1g/mL⁽¹⁰⁾. More than 80% is excreted as cefalexin in the urine. Cefalexin is acid stable. Food in the stomach causes a delay in onset, a lower peak and a prolongation of blood levels.

Approximately 10% less cefalexin is excreted in the urine of patients taking food than in that of fasting subjects.

TOXICOLOGY

Acute Toxicity

Table 5 summarizes the acute toxicity data ⁽⁹⁾, which indicate a low order of toxicity in mice, rats, cats, dogs, and monkeys when the drug is given orally. No toxicity was demonstrated until very high doses were reached. Only after single oral doses of 2 to 4.5 g/kg were employed in mice did lethargy or depression and anorexia persist for twenty-four hours. Diuresis was noted.

TABLE 5: Acute Toxicity of Cefalexin
LD₅₀ (g/kg)

SPECIES	ORAL	INTRAPERITONEAL	INTRAVENOUS
Mouse	1.6-6.2	0.4-1.6	≥ 0.7
Rat	≥ 5.0 (LD ₀)	≥ 3.65	≥ 0.7(LD ₀)
(Weanling)	≥ 4.0		
(Newborn)	≥ 3.0		
Cat	≥ 1.0 (LD ₀)	≥ 1.0	≥ 0.1(LD ₀)
Dog	≥ 2.0 (LD ₀)*	≥ 0.5 -≥ 1.0	≥ 0.1(LD ₀)
Monkey	≥ 1.0 (LD ₀)*		

* Emesis precluded a study of lethality in these species.

Although histological examination of the kidneys of animals that died revealed slight hydropic degeneration of the tubular epithelium, the cause or causes of death remain uncertain. Kidneys of some of the surviving animals showed regeneration in the tubular epithelium. Kidneys of the other mice surviving these high doses appeared normal. All blood chemistry parameters except BUN were unaffected by a 1000 mg/kg dose. The BUN concentrations increased to 200 mg in the mouse after 30 hours, but the concentrations at 72 hours were normal.

The rat was even less sensitive to cefalexin administered orally. All rats survived a 5 g/kg dose. Kidneys of these animals were found to be free of injury when examined microscopically.

In cats, dogs and monkeys, oral doses of 500 mg/kg produced salivation, emesis, and diarrhea; therefore a satisfactory study of the lethality in these species was precluded. Blood serum concentrations in the dogs and cats were as high as 200 g/mL after one and one-half hours. Twenty-four-hour trough levels were 4 g/mL or less.

A single oral dose of 400 mg/kg was well tolerated in the monkey.

From oral administration to animals, there was no indication that the pediatric formulation enhanced the toxicity of cefalexin. The largest practical dose, 40 mL/kg (1.0 g/kg), caused no deaths.

Intraperitoneal injections produced toxic effects similar to those seen after oral administration.

Subacute and Chronic Toxicity

In animal toxicology studies, organic toxicity was not encountered at doses of 400 mg/kg administered over periods of one year.

The long-term safety of cefalexin was demonstrated in one-month studies in rats, dogs, and monkeys, and one-year studies in rats and dogs. The maximum daily doses of 1000 mg/kg for dogs and monkeys were well tolerated.

The only drug-related effects in the rats were transitory growth suppression, slight diarrhea of short duration, and enlargement of caecums and colons. The dogs developed transitory appetite suppression, salivation, occasional emesis, and occasional diarrhea. Histopathologic findings were normal, although blood concentrations were as high as 200 g/mL. Short-term studies showed that dogs can tolerate even larger doses (1000 to 2000 mg/kg) with salivation and emesis as the most serious side-effects. Salivation and moderate diarrhea were the only side-effects observed in monkeys.

Intravenous doses of 15 to 60 mg/kg/day of cefalexin were well tolerated for fourteen days by rats; dogs tolerated daily intravenous injections of 7.5 to 30 mg/kg. No apparent adverse effects were observed.

Reproduction and Teratology

The fertility and reproduction of rats and mice were not affected by daily oral doses of cefalexin as great as 500 mg/kg. Skeletal abnormalities occurring in two out of twenty-two litters of mice included wavy ribs and varus limb conditions, but were not considered drug related⁽⁹⁾. The survival of the rat progeny at twelve and twenty-one days of age was significantly less than that of the control animals in one study, but was similar to the control animals in another study.

BIBLIOGRAPHY

1. Disney, FA: Cephalexin in the treatment of upper respiratory tract infections. *Postgraduate Medical Journal* 1983; 59 (6):28-31.
2. McLinn SE, Daly Jr. JF, and Jones JE: Cephalexin monohydrate suspension - treatment of otitis media. *JAMA* 1975; 234 (2):171- 173.
3. Weinstein AJ: Cephalexin in the therapy of infections of the urinary tract. *Postgraduate Medical Journal* 1983; 59 (5):40-42.
4. Herrell WE: Cephalexin in chronic bone infections. *Clinical Medicine* 1971; 78:15-16.
5. Nelson JD, Bucholz RW, Kllsmiesz H. et al: Benefits and risks of sequential parenteral-oral cephalosporin therapy for supplicative bone and joint infections. *Journal of Pediatric Orthopedics* 1982; 2 (3):255-262.
6. Dillon, Jr. HC: Treatment of staphylococcal skin infections: a comparison of cephalexin and dicloxacillin. *Journal of the American Academy of Dermatology* 1983; 8(2) 177-181.
7. Dimattia AF, Sexton MJ, Smialowicz CR, et al: Efficacy of two dosage schedules of cephalexin in dermatologic infections. *The Journal of Family Practice* 1981;12(4):649-652.
8. Burt RAP: A review of the drug events reported by 12,917 patients treated with cephalexin. *Postgraduate Medical Journal* 1983; 59(5):47-50.
9. Welles JS, Froman RO, Gibson WR, et al: Toxicology and pharmacology of cephalexin in laboratory animals. *Antimicrobial Agents and Chemotherapy* 1968; 489.
10. Griffith RS, Black HR: Ten years of cephalosporins. *Infectious Disease Reviews* 1976; 4:275-310.
11. Jones RN, Preston DA: The antimicrobial activity of cephalexin against old and new pathogens. *Postgraduate Medical Journal* 1983; 59(5):9-15.
12. Smith IM: Cephalexin: clinical effectiveness in geriatric patients. *Geriatrics* 1977; 32(3):91-99.
13. Stillerman M, Aronovitz GH, Durnell MD, et al: Comparison between cephalexin two- and four-time per day regimens in group a streptococcal pharyngitis. *Clinical Pediatrics* 1984; 23(6):348-351.
14. Maguire GP, Lee M, Lyons HA: Effectiveness of twice-daily cephalexin in the treatment of pneumococcal pneumonia. *Current Therapeutic Research* 1986; 39(4):549-553.
15. Speight TM, Brogden RN, Avery GS: Cephalexin: a review of its antibacterial, pharmacological and therapeutic properties. *Drugs* 1972; 3(1--2):9-78.

16. Product Monograph KEFLEX[®] (Cephalexin Tablets and Oral Suspension, 250 mg, 500 mg, 125 mg/5 mL and 250 mg/5 mL). PENDOPHARM, Division of Pharmascience Inc. Date of Revision: May 1, 2018 (Control No.: 210960).

17. Product Monograph - APO-CEPHALEX (Cephalexin Tablets USP) Tablets 250 mg and 500 mg. APOTEX Inc., Date of Revision: August 8, 2018. Control Number: 217227.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

Pr AURO-CEPHALEXIN

Cefalexin Tablets, BP

250 mg and 500 mg

Read this carefully before you start taking AURO-CEPHALEXIN and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about AURO-CEPHALEXIN.

What is AURO-CEPHALEXIN used for?

- AURO-CEPHALEXIN is used to treat certain bacterial infections in the:
 - respiratory tract;
 - ear (otitis media);
 - genitals and urinary tract;
 - bones and joints;
 - skin and soft tissue.
- Antibacterial drugs like AURO-CEPHALEXIN treat only bacterial infections. They do not treat viral infections, such as the common cold.

How does AURO-CEPHALEXIN work?

AURO-CEPHALEXIN is an antibiotic that:

- Stops the growth of bacteria
- Kills bacteria

What are the ingredients in AURO-CEPHALEXIN?

Medicinal ingredients: Cefalexin Monohydrate

Non-medicinal ingredients:

Sodium Starch Glycolate, Microcrystalline Cellulose, Magnesium Stearate, hypromellose, titanium dioxide, macrogol and FD&C Yellow #6 Sunset yellow FCF Aluminium Lake.

AURO-CEPHALEXIN comes in the following dosage forms:

Cefalexin Tablets, BP 250 mg and 500 mg

Do not use AURO-CEPHALEXIN if:

- you are allergic to cefalexin, cephalosporin antibiotics or to any of the other ingredients in AURO-CEPHALEXIN

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take AURO-CEPHALEXIN. Talk about any health conditions or problems you may have, including if you:

- you are allergic to or react badly to penicillins or other antibiotics.
- you have intestinal or bowel problems.
- you have kidney problems.
- you are pregnant or plan to be pregnant.
- you are breast-feeding or plan to breast-feed.

Other warnings that you should know about:

- Using antibiotics like AURO-CEPHALEXIN may cause with Clostridium difficile-associated disease

(CDAD). See “Serious side effects and what to do about them”, below.

- AURO-CEPHALEXIN may interfere with some blood and urine test results. Talk to your doctor if you are given a blood or urine test while taking AURO-CEPHALEXIN.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

How to take AURO-CEPHALEXIN:

- Take AURO-CEPHALEXIN orally on an empty stomach.
- Although you may feel better early in treatment, AURO-CEPHALEXIN should be used exactly as directed.
- Misuse or overuse of AURO-CEPHALEXIN could lead to the growth of bacteria that will not be killed by AURO-CEPHALEXIN (resistance). This means that AURO-CEPHALEXIN may not work for you in the future.
- Do not share your medicine.

Usual dose:

Adult:

The adult dosage ranges from 1 to 4 g daily in divided doses. The usual adult dose is 1 g/day in divided doses every 6 hours.

Children:

The recommended daily dosage for children is 25 to 50 mg/kg/day in divided doses every 6 hours.

Overdose:

Symptoms of oral overdose may include:

- nausea
- vomiting
- abdominal pain
- diarrhea
- bloody urine

If you think you have taken too much AURO-CEPHALEXIN, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

What are possible side effects from using AURO-CEPHALEXIN?

These are not all the possible side effects you may feel when taking AURO-CEPHALEXIN. If you experience any side effects not listed here, contact your healthcare professional.

You may experience diarrhea, nausea, vomiting, loose stools, abdominal pain, diaper rash, inflammation of the vagina or discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations or symptoms that you do not understand. You should tell your health professional for of any of these symptoms as soon as possible.

Vertigo (loss of balance or unsteadiness), tinnitus (ringing in the ears), hearing loss and behavioural changes in young children have been reported.

AURO-CEPHALEXIN may also cause effects such as yellowing of the whites of the eyes or skin (jaundice) or the inflammation of the liver (hepatitis).

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
RARE			
Symptoms of a severe bowel condition (<i>Clostridium difficile</i> colitis): <ul style="list-style-type: none"> • persistent diarrhea • bloody or watery diarrhea • abdominal or stomach pain/cramping • blood/mucus in stool 			√
Severe skin reactions: <ul style="list-style-type: none"> • skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) • widespread rash with blisters and skin peeling on much of the body surface particularly around the mouth, nose, eyes and genitals. 			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature (15°C to 30°C).

Keep out of reach and sight of children.

If you want more information about AURO-CEPHALEXIN:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>); the manufacturer’s website www.auropharma.ca, or by calling 1-855-648-6681.

This leaflet was prepared by

Auro Pharma Inc.

3700 Steeles Avenue West, Suite # 402

Woodbridge, Ontario, L4L 8K8,

Canada.

Date of Revision: September 11, 2019.